Together, these findings also support a more generalised model in which activated forms of KRAS or AKT directly and/or indirectly increase levels of YB-1 levels, which, in turn, promote an elevated HIF1α response and potentially other cytoprotective programmes required for tumour formation in vivo. The gene discussed is AKT1; the disease is neoplasm.